No Data
No Data
No Data
No Data
No Data
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully
Yahoo FinanceApr 15 06:03 ET
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
TipRanksFeb 15 14:25 ET
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?
TipRanksFeb 15 01:02 ET
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,The company's primary focus
BenzingaFeb 14 11:37 ET
Express News | Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Moomoo 24/7Feb 13 16:44 ET
Express News | Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Moomoo 24/7Feb 13 16:43 ET
No Data
No Data